All In Biotech

Drug Trial Radar · NCT04747002

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "DSP-7888" for Acute Myeloid Leukemia Patients.

Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 12, 2020

Primary completion

Mar 2024

Study completion Apr 2024

Sponsor

Lead sponsor
Osaka UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Japan Agency for Medical Research and Development
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute myeloid leukemia patients with 1st hematological complete remission (CR). DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

Conditions

  • Acute Myeloid Leukemia in Remission

Interventions

  • DSP-7888Drug

    Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse-free survivalTime frame: 2 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Osaka University

    Suita, Osaka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.